Beam Therapeutics focuses on base editing technology, which allows for precise changes at the DNA level and potentially reduces off-target effects. Base editing has the versatility to correct a wide ...

Like the human immune system, bacteria learn from past infections. CRISPR sequences—short snippets of DNA from previous viruses—guide destructive enzymes towards invading bacteriophages that express ...

A collaboration between Visual Science and Skoltech reveals the details of the CRISPR Gene Editing Technique in this 3D animation. CRISPR-Cas9 editing has proved a promising technology. It has been ...

CyDENT represents a revolutionary advancement in genetic modification, facilitating CRISPR-free base editing within mitochondria and chloroplasts. This breakthrough technology heralds a new era in ...

With a shared purpose, we can realize the true promise of CRISPR and improve healthcare, providing hope to more patients with ...

Scientists at St. Jude Children’s Research Hospital report that they have developed an unbiased, sensitive, and resource-efficient method to identify small, off-target sites that pose a safety risk ...

A major CRISPR breakthrough came last May. Researchers at Penn Medicine and the Children’s Hospital of Philadelphia developed a personalized base-editing treatment in just 6 months. The treatment was ...

CRISPR-Cas9 gene editing relies on a guide RNA that binds to a desired DNA sequence and a Cas9 enzyme that cuts both strands of DNA at that site, creating a double-strand break. Scientists edit the ...

The ambitious idea of using CRISPR to cure genetic diseases before birth is one step closer to reality. Scientists reported on Monday that they used a form of the technology known as “base editing” to ...

Scientists have worked tirelessly to develop ever more precise and efficient CRISPR-Cas systems to reach the ultimate goal: safe and effective CRISPR-Cas-based medical treatments. Over the years, ...

Beam Therapeutics has presented the first clinical data on its base editing technology. All four sickle cell disease patients in the efficacy cohort had fetal hemoglobin levels above Beam’s target—and ...